Canaccord Genuity Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $75
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Canaccord Genuity analyst Whitney Ijem initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Buy rating and announces Price Target of $75.
Canaccord Genuity analyst Whitney Ijem initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Buy rating and announces Price Target of $75.
